11.26
+5.33%
Close of 4 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Churchill Capital Corp XI
From its filings with the US Securities and Exchange Commission
Churchill Capital Corp XI is based in New York, New York and is incorporated in Cayman Islands. Its shares trade on Nasdaq under the ticker CCXI. The SEC classifies its business as general industrial machinery & equipment, nec.
Business Combination with one or more businesses or entities. We may pursue an initial Business Combination in any business or industry.
Public Units (and underlying securities), except as otherwise disclosed in the IPO Registration Statement.
Combination Period consistent with applicable laws, regulations and stock exchange rules by amending our Amended and Restated Articles.
If we do not meet the Nasdaq 36-Month Requirement, our securities will likely be subject to suspension of trading and delisting from Nasdaq.
Klein and Company has established strategic relationships with selected leading investors and financing providers (“Strategic Partners”).
M. Klein and Company’s or our Strategic and Operating Partners’ performance as indicative of our future performance.
Operating Partners, will materially affect our ability to complete our initial Business Combination.
Additionally, pursuant to Nasdaq rules, any initial Business Combination must be approved by a majority of our independent directors.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Feb 2012
- Employees
- 82
- Website
- chemocentryx.com ↗
- Head office
- 640 FIFTH AVENUE 12TH FLOOR, NEW YORK, NY, 10019
- Incorporated in
- E9
- Classification
- General Industrial Machinery & Equipment, NEC
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Thomas SchallChairman of the Board, President, Chief Executive Officer, since 1997$9.0m
- Ms. Susan KanayaChief Financial and Administrative Officer, Executive Vice President, Secretary, Director, since 2006$3.9m
- Mr. Tausif ButtChief Operating Officer, Executive Vice President$5.9m
- Dr. Rita JainExecutive Vice President, Chief Medical Officer, Director, since 2019$1.0m
- Dr. Markus CappelChief Business Officer, Treasurer$2.6m
- Mr. Thomas EdwardsLead Independent Director$213,761
- Dr. Joseph FeczkoIndependent Director$192,761
- Ms. Jennifer HerronIndependent Director
- Mr. Geoffrey ParkerIndependent Director$176,859
- Mr. James TyreeIndependent Director$196,261
- Dr. David WheadonIndependent Director
- Mr. Bill SlatteryVice President - Investor Relations and Corporate Communications, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ChemoCentryx Inc possesses several key strengths that contribute to its competitive advantage and success in the pharmaceutical industry:
Weaknesses
- Despite its strengths, ChemoCentryx Inc also faces certain weaknesses that pose challenges to its growth and sustainability:
Opportunities
- ChemoCentryx Inc can capitalize on the following opportunities to expand its market presence and achieve further growth:
Threats
- ChemoCentryx Inc should be aware of the following threats that could hinder its growth and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.